Online And Pharma Execution Risks Will Test Pet Health Upside Potential

Catalysts

About Swedencare

Swedencare develops and sells pet health products across dental care, nutraceuticals, treats and veterinary pharma, with a growing focus on online and Big Box retail channels.

What are the underlying business or industry changes driving this perspective?

• Although NaturVet, ProDen PlaqueOff and Riley's show solid online and retail traction, heavy Amazon marketing, rogue sellers and discounting have weighed on profitability. Tighter control through the transparency program and completed rebranding mainly represents a test of whether online growth can translate into higher gross margin and EBITDA.
• While pet ownership and premiumisation support demand for dental products, nutraceuticals and premium treats like Riley's, the previous spike in marketing spend for Big Box launches and low margin display activity at Walmart means any benefit from higher volumes could be partly offset if future retail campaigns again run ahead of revenue, with mixed implications for operating margin.
• Although the pharma division now has signed material projects and expanded ophthalmic capacity, past delays and project postponements show execution risk remains. The extent to which this business can contribute higher margin sales and EBITDA is still dependent on timely tech transfers and manufacturing ramp up.
• While Swedencare is building an internal manufacturing base and has increased internal revenue, the Production segment has seen weaker contract manufacturing and cautious vet demand. Any shift of more volume in house could help gross margin only if external customer volumes stabilise and fixed costs are absorbed more efficiently.
• Although pet health brands such as ProDen PlaqueOff and NaturVet have shown the ability to reach double digit organic growth, selective pricing actions and product launches like the upgraded K2C line and Calmalia will only support revenue and earnings if consumers accept higher price points and retailers maintain shelf space without requiring disproportionate promotional spend.

Assumptions

This narrative explores a more pessimistic perspective on Swedencare compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Swedencare's revenue will grow by 6.9% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 2.1% today to 9.9% in 3 years time.
• The bearish analysts expect earnings to reach SEK 324.8 million (and earnings per share of SEK 2.05) by about February 2029, up from SEK 55.5 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK367.8 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 22.8x on those 2029 earnings, down from 71.1x today. This future PE is lower than the current PE for the SE Pharmaceuticals industry at 57.2x.
• The bearish analysts expect the number of shares outstanding to grow by 0.62% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.22%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Execution issues in online channels, such as rogue Amazon sellers, MAP violations and the need for higher Amazon marketing to defend the buy box, could keep pricing under pressure and force Swedencare to spend more on promotion than it recoups in sales. This would weigh on gross margin and EBITDA.
• Big Box and pet retail campaigns, including costly Walmart display initiatives and new brand launches like Vet Worthy, may continue to require heavy up front marketing and promotional support that is not fully matched by sell through. This would limit the contribution of higher volumes to operating margin and earnings.
• Pharma and contract manufacturing projects have already seen postponements and weaker vet channel demand. Further delays in tech transfers, order push outs or slow capacity ramp up could restrict higher margin pharma revenue and reduce the group EBITDA margin compared with management’s longer term targets.
• Currency headwinds, such as the stronger krona against the US dollar, euro and pound that affected reported growth, could persist and dilute the translated value of North American and European sales and profits. This would constrain reported revenue and earnings even if volumes hold up.
• Higher inventory write offs linked to discontinued product lines, acquired stock and brand refocusing, combined with ERP related disruptions that slow shipments, could reoccur if product and supply chain planning do not fully stabilize. This would pressure gross margin and operating EBITDA.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Swedencare is SEK39.0, which represents up to two standard deviations below the consensus price target of SEK47.0. This valuation is based on what can be assumed as the expectations of Swedencare's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK55.0, and the most bearish reporting a price target of just SEK39.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be SEK3.3 billion, earnings will come to SEK324.8 million, and it would be trading on a PE ratio of 22.8x, assuming you use a discount rate of 5.2%.
  
• Given the current share price of SEK24.7, the analyst price target of SEK39.0 is 36.7% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.